HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


L’Oréal Plans Largest Deal: $2.52Bn For Aesop

Executive Summary

L’Oréal plans to acquire Australian luxury beauty brand Aesop from Natura & Co. in third quarter, subject to regulatory approvals, marking its biggest acquisition to date.

You may also be interested in...

Cosmetics News: Natura Sells The Body Shop; e.l.f. Launches Roblox Experience; DIY Nailbot STEM Kit; More

Natura says its sale of The Body Shop to international private equity group Aurelius – following its divestiture of Aesop to L’Oreal in a deal that closed in August – is another step toward simplifying operations and refocusing on strategic priorities. More cosmetics news.

L’Oreal CEO On New Lancôme Shop On Amazon: ‘You Can Truly Reach New Consumers’

L’Oréal’s Lancôme Brand Store on Amazon, launched in early 2023, is a powerful new digital platform where early data suggest 75% of shoppers are new to the brand, said CEO and director Nicolas Hieronimus during the firm’s 19 October third-quarter earnings presentation.

L’Oreal’s Consumer Products, Dermatological Divisions In ‘Hyperdrive’; H1 Sales Leap 13%

L’Oreal’s organic top-line growth has been 8.2% on a compound annual basis since the start of 2019. The beauty giant’s overall net sales totaled roughly 3.74bn for the first half of 2023, an increase of 13.3% like-for-like, reflecting outstanding, broad-based performances across the business.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts